Daily Sepsis Research Analysis
Three advances span precision immunophenotyping, sedation strategy, and infection prevention in sepsis. A four-gene blood panel stratified sepsis immune status and identified endotypes where hydrocortisone or thymosin was associated with harm; dexmedetomidine reduced 28-day mortality in septic shock versus non-dexmedetomidine sedatives; and real-world evidence linked SGLT2 inhibitors to lower risks of pneumonia and sepsis in type 2 diabetes.
Summary
Three advances span precision immunophenotyping, sedation strategy, and infection prevention in sepsis. A four-gene blood panel stratified sepsis immune status and identified endotypes where hydrocortisone or thymosin was associated with harm; dexmedetomidine reduced 28-day mortality in septic shock versus non-dexmedetomidine sedatives; and real-world evidence linked SGLT2 inhibitors to lower risks of pneumonia and sepsis in type 2 diabetes.
Research Themes
- Precision immuno-endotyping in sepsis to guide therapy
- Sedation choice and outcomes in septic shock
- Metabolic therapies and infection risk reduction in diabetes
Selected Articles
1. Development of a gene panel for immune status assessment in sepsis.
A four-gene blood panel (TBX21, GNLY, PRF1, IL2RB) accurately captured immune status in sepsis (external-validation AUROC 0.891–0.909) and defined endotypes with differential response signals. In the high-expression endotype, hydrocortisone and thymosin were associated with increased 90-day mortality, highlighting the risk of indiscriminate immunotherapy.
Impact: Introduces a practical precision-immunology tool with direct implications for avoiding harmful immunotherapies in specific sepsis endotypes.
Clinical Implications: Endotype-aware decision-making could prevent harm from hydrocortisone or thymosin in immune-activated endotypes and prioritize trials of targeted immunomodulation.
Key Findings
- Identified a 4-gene panel (TBX21, GNLY, PRF1, IL2RB) representing immune status in sepsis with AUROC 0.891–0.909 in external validation.
- Clustering 99 double-blind randomized sepsis patients into two endotypes showed the high-expression endotype had increased 90-day mortality with hydrocortisone (OR 12.46) and thymosin (OR 4.17).
- Findings support using transcriptomic endotyping to guide immunotherapy decisions in sepsis.
Methodological Strengths
- External validation across multiple machine learning models with high AUROC.
- Prospective, double-blind randomized patient cohort used for endotyping analysis; registered study.
Limitations
- Therapeutic effects were not randomized by endotype; findings are post hoc regarding treatment-endotype interaction.
- Single-country cohort with modest sample size; real-time clinical implementation and assay turnaround not assessed.
Future Directions: Prospective, endotype-stratified randomized trials testing immunotherapies; validation of rapid assay workflows and generalizability across diverse populations.
BACKGROUND: Sepsis is characterized by a dysregulated immune response to infection, with a balance between hyperinflammation and immunosuppression, which determines the patient's immune status. Real-time monitoring of the immune status in sepsis is crucial for guiding immunotherapy. However, reliable biomarkers are lacking. This study aims to identify a panel of biomarkers for rapid bedside assessment of immune status in sepsis to guide immunotherapy decisions. RESULTS: TBX21, GNLY, PRF1, and IL2RB represent the immune status in sepsis. These genes demonstrated discriminatory power in the external validation, with area under the curve values ranging from 0.891 to 0.909 across several machine learning models. 99 double-blind randomized patients with sepsis were clustered into two endotypes on the basis of the expression of the four-gene panel. Higher 90-day mortality was observed in patients with sepsis treated with hydrocortisone (Odds ratio 12.46, 95% confidence intervals 3.11 to 65.72) or thymosin (Odds ratio 4.17, 95% confidence intervals 1.13 to 16.51) within the high-expression 4-gene panel endotype, but not in another endotype. CONCLUSIONS: The results support the potential utility of a four-gene panel to assess immune status and guide immunotherapy; further prospective validation and translational studies are warranted. Trial registration National Medical Research Registration and Filing Information of China, 2022ZDSYLL196-P01. Registered 26 May 2023, https://www.medicalresearch.org.cn/login.
2. Is dexmedetomidine superior to non-dexmedetomidine sedatives (particularly propofol) for sedation in critically ill patients with septic shock? A systematic review and meta-analysis of randomized controlled trials.
Across 17 RCTs in septic shock, dexmedetomidine reduced 28-day mortality versus non-dexmedetomidine sedatives without excess hemodynamic adverse events. No significant differences were detected when directly compared with propofol.
Impact: Aggregates randomized evidence to inform sedation choice in septic shock—an everyday decision with mortality implications.
Clinical Implications: When feasible, dexmedetomidine may be preferred over non-DEX sedatives in septic shock. Equivalence with propofol remains uncertain; individual hemodynamics and resource factors should guide choice pending definitive head-to-head trials.
Key Findings
- Pooled 17 RCTs (n=1,422) showed dexmedetomidine reduced 28-day mortality versus non-DEX sedatives (OR 0.68, 95% CI 0.49–0.94).
- No significant difference between dexmedetomidine and propofol in available head-to-head data.
- No increase in hemodynamic adverse events with dexmedetomidine.
- Protocol registered and trial sequential analysis conducted to assess information size.
Methodological Strengths
- Prospectively registered meta-analysis of RCTs with trial sequential analysis.
- Focused population (septic shock) and clinically relevant outcomes (28-day mortality).
Limitations
- Heterogeneity in sedation protocols, co-interventions, and depth/targets across trials.
- Insufficient head-to-head data to conclude superiority versus propofol; risk of small-study effects cannot be excluded.
Future Directions: Large, pragmatic RCTs directly comparing dexmedetomidine and propofol with standardized sedation targets and hemodynamic endpoints in septic shock.
BACKGROUND: Dexmedetomidine (DEX) and propofol (PROP) are both recommended as first-line short-acting sedative-analgesic agents for sepsis patients. However, existing studies have reported inconsistent clinical outcomes potentially attributable to their distinct hemodynamic profiles. The aim of our study was to systematically evaluate the comparative clinical efficacy and safety of DEX vs. non-Dexmedetomidine sedatives (particularly Propofol) in patients with septic shock. METHODS: The study protocol was prospectively registered on PROSPERO (CRD42024626139). Randomized controlled trials (RCTs) meeting eligibility criteria were systematically searched up to December 2024. Statistical analyses were performed using RevMan 5.4, and trial sequential analysis (TSA) was employed to determine the required sample size. RESULTS: 17 RCTs were enrolled with 1,422 patients. Compared with non-DEX group, DEX group presented significantly reduced 28-day mortality (odds ratio [OR] 0.68, 95% CI 0.49-0.94, CONCLUSION: DEX demonstrated superiority over non-DEX sedatives in critically ill patients with septic shock without increasing hemodynamic adverse events. However, current evidence showed no significant differences between DEX and PROP, warranting further high-quality RCTs for definitive conclusions.
3. SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence.
Across real-world observational studies, SGLT2 inhibitor use in type 2 diabetes was associated with reduced risks of pneumonia, pneumonia-related mortality, and sepsis, while showing no association with COVID-19 mortality or hospitalization.
Impact: Connects a widely used metabolic therapy to lower serious infection and sepsis risk, with potential implications for prescribing decisions in high-risk populations.
Clinical Implications: When clinically appropriate, SGLT2 inhibitors may confer infection-related benefits, including lower sepsis risk, in type 2 diabetes. Clinicians should balance genitourinary adverse events with potential systemic infection benefits.
Key Findings
- Meta-analyses of real-world studies found reduced pneumonia risk (HR 0.61), pneumonia-related mortality (HR 0.49), and sepsis risk (HR 0.45) with SGLT2 inhibitor use.
- No association was observed with COVID-19-related mortality (OR 0.91) or hospitalization (OR 0.90).
- Search and protocol were prospectively registered (PROSPERO), synthesizing 28 studies (14 meta-analyses).
Methodological Strengths
- Prospectively registered systematic review with focused non-genitourinary infection outcomes.
- Quantitative synthesis with consistent directionality across multiple cohorts.
Limitations
- Observational design introduces residual confounding and channeling bias; effect sizes may be influenced by healthy-user effects.
- Heterogeneity in definitions and adjustment sets across databases; limited number of studies for sepsis endpoint.
Future Directions: Emulation of target trials and, where feasible, randomized pragmatic studies to test infection and sepsis outcomes; mechanistic studies on immunometabolic effects of SGLT2 inhibition.
BACKGROUND: People with diabetes are at increased risk of infections. Emerging evidence suggests sodium-glucose cotransporter 2 (SGLT2) inhibitors have pleiotropic effects that may protect against certain infections. We systematically reviewed real-world evidence on the association between SGLT2 inhibitors and infections among adults with Type 2 diabetes. METHODS: We searched Medline, Embase, Scopus, and Google Scholar from January 1, 2012 to March 18, 2024 for observational studies conducted in adults with Type 2 diabetes published in English. The exposure was SGLT2 inhibitors, and comparators were nonusers or users of other glucose-lowering medications. Studies reporting outcome estimates for specific non-genitourinary infections were included. The study was prospectively registered with PROSPERO (CRD42023492265). RESULTS: From 6827 records, 28 studies were included in qualitative synthesis and 14 in meta-analyses. There was no association with COVID-19-related mortality in seven studies (OR 0.91; 95% CI: 0.57-1.46) or COVID-19-related hospitalisation in three studies (OR 0.90; 95% CI: 0.67-1.20). A reduced risk of pneumonia was observed in three studies (HR: 0.61; 95% CI: 0.57-0.66), a reduced risk of pneumonia-related mortality in two studies (HR: 0.49; 95% CI: 0.35-0.67), and a reduced risk of sepsis in three studies (HR: 0.45; 95% CI: 0.30-0.68). CONCLUSION: Real-world evidence suggests SGLT2 inhibitors are associated with lower risk of pneumonia, pneumonia-related mortality and sepsis. Given the high burden of infection in this population, these associations deserve further research.